ArticleOncology reports2026
HDAC1 promotes lung adenocarcinoma progression via the nuclear accumulation of β‑catenin.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone deacetylase 1 (HDAC1) is frequently dysregulated in various human malignancies; however, the molecular mechanisms underlying its role in non‑small cell lung cancer (NSCLC) remain unclear. HDAC1 expression was evaluated in 157 paired lung adenocarcinoma (LUAD) and adjacent non‑neoplastic tissues using tissue microarray and immunohistochemical analysis. The functional role of HDAC1 was assessed in A549, H1299 and H1975 NSCLC cells following stable knockdown or overexpression, using Cell Counting Kit‑8, colony formation and Transwell assays. Downstream signaling was examined by western blotting and nuclear‑cytoplasmic fractionation. Rescue experiments were performed by overexpressing β‑catenin in HDAC1‑knockdown cells and the findings were further validated in a subcutaneous xenograft tumor model in nude mice. HDAC1 was markedly upregulated in LUAD tissues and associated with lymph node metastasis and poor differentiation. Functionally, HDAC1 knockdown inhibited proliferation, colony formation, migration and invasion in all three NSCLC cell lines. These effects were accompanied by downregulation of c‑Myc, cyclin D1 and vimentin, upregulation of E‑cadherin and reduced nuclear β‑catenin accumulation. Conversely, HDAC1 overexpression enhanced malignant phenotypes and promoted β‑catenin nuclear accumulation. Notably, the phosphorylation of AKT (Thr308 and Ser473) and ERK1/2 remained unaltered following HDAC1 modulation. β‑catenin overexpression effectively eliminated the tumor‑suppressive effects of HDAC1 knockdown both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.